tradingkey.logo

Dare Bioscience Inc

DARE
查看详细走势图
2.170USD
+0.010+0.46%
收盘 12/24, 16:00美东报价延迟15分钟
30.23M总市值
亏损市盈率 TTM

Dare Bioscience Inc

2.170
+0.010+0.46%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+0.46%

5天

-4.82%

1月

+22.60%

6月

-17.80%

今年开始到现在

-30.45%

1年

-32.19%

查看详细走势图

TradingKey Dare Bioscience Inc股票评分

单位: USD 更新时间: 2025-12-24

操作建议

Dare Bioscience Inc当前公司基本面数据相对健康,增长潜力较大。当前估值合理,在药品行业排名93/158位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价10.75。中期看,股价处于平稳状态。近一个月,市场表现很强,技术面评分较高,但很强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Dare Bioscience Inc评分

相关信息

行业排名
93 / 158
全市场排名
255 / 4562
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 4 位分析师
买入
评级
10.750
目标均价
+484.24%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Dare Bioscience Inc亮点

亮点风险
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
业绩增长期
公司处于发展阶段,最新年度总收入9.78K美元
估值合理
公司最新PE估值-1.19,处于3年历史合理位
先锋集团持仓
明星投资者先锋集团持仓,最新持仓市值394.90K
活跃度降低
近期活跃度降低,过去20天平均换手率-0.66

Dare Bioscience Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Dare Bioscience Inc简介

Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
公司代码DARE
公司Dare Bioscience Inc
CEOJohnson (Sabrina Martucci)
网址https://www.darebioscience.com/

常见问题

Dare Bioscience Inc(DARE)的当前股价是多少?

Dare Bioscience Inc(DARE)的当前股价是 2.170。

Dare Bioscience Inc的股票代码是什么?

Dare Bioscience Inc的股票代码是DARE。

Dare Bioscience Inc股票的52周最高点是多少?

Dare Bioscience Inc股票的52周最高点是9.190。

Dare Bioscience Inc股票的52周最低点是多少?

Dare Bioscience Inc股票的52周最低点是1.610。

Dare Bioscience Inc的市值是多少?

Dare Bioscience Inc的市值是30.23M。

Dare Bioscience Inc的净利润是多少?

Dare Bioscience Inc的净利润为-4.05M。

现在Dare Bioscience Inc(DARE)的股票是买入、持有还是卖出?

根据分析师评级,Dare Bioscience Inc(DARE)的总体评级为买入,目标价格为10.750。

Dare Bioscience Inc(DARE)股票的每股收益(EPS TTM)是多少

Dare Bioscience Inc(DARE)股票的每股收益(EPS TTM)是-1.824。
KeyAI